View Older Stories View More Recent Stories
-
Leerink Defending Sarepta Therapeutics (SRPT): 'the stock reaction for SRPT is overdone'
-
JPMorgan Comments on Sarepta Therapeutics (SRPT)
-
TD Cowen Reiterates Buy Rating on Sarepta Therapeutics (SRPT) following Elevidys death
-
Mizuho sees Sarepta Therapeutics (SRPT) sell-off on elevidys death 'likely an overreaction'
-
BofA Defending Sarepta Therapeutics (SRPT): 'Risk-benefit profile of Elevidys remains favorable despite death report'
-
Sarepta Therapeutics (SRPT) Shares Safety Update on ELEVIDYS
-
Sarepta Therapeutics (SRPT) Plunges 20% Pre-Open, Reason For Drop Unclear
-
Scotiabank Starts Sarepta Therapeutics (SRPT) at Sector Perform
-
Cantor Fitzgerald Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
-
Sarepta Therapeutics (SRPT) files mixed shelf
-
RBC on Sarepta Therapeutics (SRPT): 'Overall We View Shares as Fundamentally Undervalued'; PT Lowered
-
Sarepta Therapeutics (SRPT) PT Lowered to $190 at Mizuho
-
Sarepta Therapeutics (SRPT) Tops Q4 EPS by 36c
-
Deutsche Bank Starts Sarepta Therapeutics (SRPT) at Hold
-
Arrowhead Pharmaceuticals (ARWR) Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics (SRPT)
-
BMO Capital Reiterates Outperform on Sarepta Therapeutics (SRPT) Following Part-2 Data from Elevidys PhIII
-
Morgan Stanley Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
-
Mizuho Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
-
H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)
-
Piper Sandler on Sarepta Therapeutics (SRPT): 'SRPT Outperforms Revenue Guidance Driven By Elevidys'
-
RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
-
Sarepta Therapeutics (SRPT) Reports Preliminary Fourth Quarter and Full-Year 2024 Net Product Revenue
-
BMO Capital Reiterates Outperform Rating on Sarepta Therapeutics (SRPT), Says DM1 Data Could Move Stock
-
RBC report: Biotech faces both uncertainty and growth opportunities in 2025
-
BMO Capital Highlights Favorite Names for 2025 in Biotech
-
RBC Capital's Game Changers: 'Disruptive Forces in Biotech'
-
RBC Capital's Global Biotech Outlook Report: 'Top 2025 Ideas'
-
Sarepta Therapeutics (SRPT) PT Lowered to $75 at H.C. Wainwright
-
BMO Capital Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
-
Sarepta Therapeutics (SRPT) PT Lowered to $182 at Piper Sandler
-
Sarepta Therapeutics (SRPT) PT Lowered to $202 at Needham
-
Morgan Stanley Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
-
Mizuho Reiterates Outperform Rating on Sarepta Therapeutics (SRPT) on Arrowhead (ARWR) deal
-
Arrowhead Pharmaceuticals (ARWR) Climbs 32% Following Pact with Sarepta Therapeutics (SRPT)
-
Sarepta Therapeutics (SRPT) Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals (ARWR) for Multiple Clinical and Preclinical siRNA Programs
-
Piper Sandler Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
-
Sarepta Therapeutics (SRPT) PT Lowered to $193 at Baird
-
Cantor Fitzgerald Upgrades Sarepta Therapeutics (SRPT) to Overweight
-
Sarepta Therapeutics (SRPT) Tops Q3 EPS by 68c
-
Jefferies Starts Sarepta Therapeutics (SRPT) at Buy
-
Barclays Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
-
Raymond James Resumes Sarepta Therapeutics (SRPT) at Outperform
-
Mizuho Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
-
BMO on Sarepta (SRPT): 'Long-Term Elevidys Data Support Uptake & Competitive Positioning'
-
RBC makes changes to its Top 30 Global Ideas for 2024
-
TD Cowen Reiterates Buy Rating on Sarepta Therapeutics (SRPT)
-
Sarepta Therapeutics (SRPT) Appoints Deirdre Connelly to its Board
-
BMO Capital Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
-
TD Cowen Reiterates Buy Rating on Sarepta Therapeutics (SRPT)
-
Evercore ISI Upgrades Sarepta Therapeutics (SRPT) to Outperform
